126 related articles for article (PubMed ID: 31123858)
1. Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
de Castro CL; da Costa Junior LC; Lourenço LV; Seba KS; da Silva TSL; Vianna-Jorge R
Arch Gynecol Obstet; 2019 Aug; 300(2):395-407. PubMed ID: 31123858
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
da Costa Junior LC; de Castro CL; Freitas-Alves DR; Vianna-Jorge R; Santos PCJL
Eur J Clin Pharmacol; 2020 Oct; 76(10):1401-1408. PubMed ID: 32564116
[TBL] [Abstract][Full Text] [Related]
3. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
Vergote I; Debruyne P; Kridelka F; Berteloot P; Amant F; Honhon B; Lybaert W; Leunen K; Geldhof K; Verhoeven D; Forget F; Vuylsteke P; D'Hondt L; Huizing M; Van den Bulck H; Laenen A
Gynecol Oncol; 2015 Aug; 138(2):278-84. PubMed ID: 26049123
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
9. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
12. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
13. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
15. Hematological toxicity of carboplatin for gynecological cancer according to body mass index.
Gutierrez F; Gonzalez-de-la-Fuente GA; Nazco GJ; Oramas J; Batista N
Eur J Clin Pharmacol; 2016 Sep; 72(9):1083-9. PubMed ID: 27287195
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
18. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
